[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496826":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":28,"overallOfficials":36,"centralContacts":41,"locations":51,"responsibleParty":69,"collaborators":13,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":13,"eligibilityCriteria":76,"healthyVolunteers":73,"sex":77,"minAge":78,"maxAge":13,"enrollmentInfo":79,"targetDuration":13,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":13,"overallStatus":54,"whyStopped":13,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Diagnostic value","Sensitivity and Specificity of Al18F-octreotide PET\u002FCT for SSTR positive tumors","through study completion, an average of 1 year]",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Octreotide is an artificial replacement for the natural growth hormone inhibitor in humans. It is a small peptide hormone consisting of 14 amino acids and is widely distributed in neuroendocrine cells, with the highest density in the brain, peripheral neurons, endocrine pancreas and gastrointestinal tract. Under pathological conditions, some tumour cells show overexpression of growth inhibitory receptors, such as endocrine tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid tumours, medullary thyroid carcinomas, small cell lung carcinomas Hepatocellular carcinoma, and meningioma. Therefore, the sensitivity and specificity of octreotide imaging is high.\n\nThis study will provide a visual, reproducible and non-invasive imaging method for the diagnosis of SSTR positive tumors through Al18F-octreotide PCT\u002FCT imaging, providing an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment, contributing to the development of medicine and science in the field of positron imaging.",[22],{"label":23,"type":24,"description":25,"interventionNames":26},"Al18F-octreotide PET\u002FCT","EXPERIMENTAL","Al18F-octreotide PET\u002FCT will be performed on patients with suspected or clearly diagnosed SSTR positive tumors . The patients were injected with Al18F-octreotide and underwent PET\u002FCT scan 20\\~40min after the injection.",[27],"Drug: Al18F-octreotide",[29],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","Al18F-octreotide","Al18F-octreotide I was injected into the patients before the PET\u002FCT scans",[23],[35],"Al18F-NOTA-TATE",[37],{"name":38,"affiliation":39,"role":40},"Rong Zheng, M.D.","National Cancer Center\u002FCancer Hospital, Chinese Academy of Medical Sciences and PUMC","STUDY_DIRECTOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":13,"email":46},"Gouzhu Hou, M.D.","CONTACT","15611145656","15611145656@163.com",{"name":48,"role":44,"phone":49,"phoneExt":13,"email":50},"Xin Cheng, M.D.","15120002998","cxpumc@foxmail.com",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"National Cancer Center\u002FCancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","Chao Yang","100021","China","CN",{"type":61,"coordinates":62},"Point",[63,64],116.39723,39.9075,{"lat":64,"lon":63},[67],{"name":68,"role":44,"phone":45,"phoneExt":13,"email":46},"Guozhu Hou, M.D.",{"type":70,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100496826","phase-2-application-of-al18f-octreotide-petct-in-tumors-with-positive-sstr-expression-100496826",false,"NCT05749289","Application of Al18F-octreotide PET\u002FCT in Tumors With Positive SSTR Expression","Inclusion Criteria:\n\n* Patients with suspected or clearly diagnosed SSTR positive tumors\n* signed written consent.\n* Willing and able to cooperate with all projects in this study.\n\nExclusion Criteria:\n\n* pregnancy;\n* breastfeeding;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.","ALL","18 Years",{"count":80,"type":81},400,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE2","PHASE3","This is an open-label whole-body PET\u002FCT study for investigating the value of Al18F-octreotide PET\u002FCT in patients with SSTR positive tumors",[88],"SSTR Positive Tumors","2026-03-31",{"date":91,"type":92},"2026-04-06","ACTUAL",{"date":94,"type":92},"2022-12-20",{"date":96,"type":81},"2029-12-20",{"name":5,"class":6},1]